Galcanezumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Cluster Headache
Conditions
Episodic Cluster Headache
Trial Timeline
May 22, 2015 → Jun 4, 2018
NCT ID
NCT02397473About Galcanezumab + Placebo
Galcanezumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Episodic Cluster Headache. The current trial status is completed. This product is registered under clinical trial identifier NCT02397473. Target conditions include Episodic Cluster Headache.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04616326 | Phase 3 | Active |
| NCT04085289 | Phase 1 | Completed |
| NCT03963232 | Phase 3 | Completed |
| NCT03559257 | Phase 3 | Completed |
| NCT03432286 | Phase 3 | Active |
| NCT02959177 | Phase 2 | Completed |
| NCT02614196 | Phase 3 | Completed |
| NCT02614261 | Phase 3 | Completed |
| NCT02614183 | Phase 3 | Completed |
| NCT02576951 | Phase 1 | Completed |
| NCT02397473 | Phase 3 | Completed |
| NCT02163993 | Phase 2 | Completed |
Competing Products
19 competing products in Episodic Cluster Headache
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| Atogepant 60 mg | AbbVie | Phase 3 | 77 |
| Atogepant + Ubrogepant | AbbVie | Approved | 85 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 77 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 85 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 77 |
| Erenumab | Novartis | Phase 3 | 77 |
| Placebo + AMG 301 | Amgen | Phase 2 | 51 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 32 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 49 |
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 74 |
| Methylprednisolone | Brain Biotech | Approved | 77 |